Gilteritinib for Acute Myeloid Leukaemia (AML)

Regular price £0.00

Tax included.

Gilteritinib (Xospata, Astellas Pharma Europe B.V) is a highly specific, second-generation tyrosine kinase inhibitor which has been developed for the treatment of patients with acute myeloid leukaemia (AML) who have an FMS-like tyrosine kinase 3 (FLT3) mutation.

Please note - this is a digital download only and you will not receive a hardcopy through the post. 

All our information is available free of charge to people affected by leukaemia and associated conditions. It costs us approximately £3 to provide one booklet. Please consider adding a donation to your order if you can. 

Add donation